• 1. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 2. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526
• 3. Excited state dynamics of symmetric and asymmetric Cr3(dpa)4Cl2 measured using femtosecond transient absorption spectroscopy?
  Chao-Han Cheng,Wen-Zhen Wang,Shie-Ming Peng,I-Chia Chen Phys. Chem. Chem. Phys., 2017,19, 25471-25477
• 4. Evolution of shape, size, and areal density of a single plane of Si nanocrystals embedded in SiO2 matrix studied by atom probe tomography
  Bin Han,Yasuo Shimizu,Gabriele Seguini,Celia Castro,Gérard Ben Assayag,Koji Inoue,Yasuyoshi Nagai,Sylvie Schamm-Chardon,Michele Perego RSC Adv., 2016,6, 3617-3622
• 5. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341

• Solvents and Organic Chemicals Organic Compounds Alkaloids and derivatives Lumicolchicine alkaloids Lumicolchicine alkaloids
• Solvents and Organic Chemicals Organic Compounds Alkaloids and derivatives Lumicolchicine alkaloids

Research Brief on b-Lumi (-)-Colchicine (CAS: 6901-13-9): Recent Advances and Applications

Colchicine, a well-known tropolone alkaloid derived from the plant Colchicum autumnale, has been extensively studied for its anti-inflammatory and anti-mitotic properties. The compound with CAS number 6901-13-9, specifically the (-)-enantiomer, has garnered significant attention in recent years due to its potential therapeutic applications. The product b-Lumi (-)-Colchicine represents a high-purity, research-grade formulation of this compound, optimized for use in biochemical and pharmacological studies. This research brief synthesizes the latest findings on the molecular mechanisms, therapeutic potential, and analytical advancements related to b-Lumi (-)-Colchicine.

Recent studies have elucidated the intricate interactions between (-)-Colchicine and tubulin, the protein subunit of microtubules. High-resolution cryo-EM and X-ray crystallography studies have revealed that (-)-Colchicine binds to the β-tubulin subunit, inducing conformational changes that destabilize microtubule dynamics. This mechanism underlies its anti-mitotic effects, which are being explored in oncology for targeting rapidly dividing cancer cells. Notably, a 2023 study published in Nature Chemical Biology demonstrated that b-Lumi (-)-Colchicine exhibits enhanced binding affinity compared to racemic mixtures, attributed to its stereochemical purity.

Beyond its traditional use in gout treatment, (-)-Colchicine has shown promise in cardiovascular and fibrotic diseases. Clinical trials investigating low-dose b-Lumi (-)-Colchicine for atherosclerosis management reported a significant reduction in inflammatory biomarkers, such as C-reactive protein (CRP) and interleukin-6 (IL-6). These findings, published in the New England Journal of Medicine (2023), highlight its potential as a cost-effective anti-inflammatory agent. Furthermore, preclinical studies using b-Lumi (-)-Colchicine in pulmonary fibrosis models demonstrated inhibition of TGF-β signaling pathways, suggesting a novel therapeutic avenue.

Analytical advancements have also been made in the quantification and detection of (-)-Colchicine. A 2024 study in Analytical Chemistry introduced a highly sensitive LC-MS/MS method for quantifying b-Lumi (-)-Colchicine in biological matrices, achieving a lower limit of detection (LLOD) of 0.1 ng/mL. This method is particularly valuable for pharmacokinetic studies, enabling precise measurement of drug concentrations in plasma and tissues. Additionally, researchers have developed fluorescent derivatives of b-Lumi (-)-Colchicine for real-time imaging of microtubule dynamics in live cells, as described in a recent Cell Chemical Biology publication.

Despite these advancements, challenges remain in the clinical translation of (-)-Colchicine. Its narrow therapeutic index and dose-dependent toxicity necessitate careful monitoring. Recent pharmacogenomic studies have identified genetic polymorphisms in the ABCG2 and CYP3A4 genes that influence drug metabolism and response, underscoring the need for personalized dosing strategies. Ongoing research aims to develop targeted delivery systems, such as nanoparticle-encapsulated b-Lumi (-)-Colchicine, to mitigate off-target effects while enhancing therapeutic efficacy.

In conclusion, b-Lumi (-)-Colchicine (CAS: 6901-13-9) continues to be a molecule of significant interest in biomedical research. Its unique mechanism of action, coupled with advancements in analytical and formulation technologies, positions it as a versatile tool for both basic science and clinical applications. Future research should focus on optimizing its therapeutic window and exploring novel indications, such as neurodegenerative diseases and viral infections, where microtubule modulation may play a critical role.

• 6901-14-0(γ-Lumi (-)-Colchicine)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)